The significance of histological determination of HER-2 status in breast cancer

Breast

Volumn 9, Issue 3, 2000, Pages 130-133

  Walker, R A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TRASTUZUMAB;

BREAST CANCER; BREAST CARCINOMA; BREAST DUCT; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY;

EID: 0034076802     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2000.0167     Document Type: Article

References (39)

1. Padhly L C, Shih C, Cowing D, Finkelstein R, Weinberg R A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastoma. Cell. 28:1982;865-871.
2. Coussens L, Yang-Fen T L, Liao Y C. Tyrosine kinase receptor with extensive homology to EGF receptor shares the chromosomal location with neu oncogene. Science. 230:1985;1132-1139.
3. Semba K, Kamata N, Toyoshima K. A v- erb related proto oncogene, c- erb B-2 is distinct from c- erb B-1/epidermal growth factor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA. 82:1985;6497-6501.
4. Walker R A. The erbB/HER type 1 tyrosine kinase receptor family. J Pathol. 185:1998;234-235.
5. Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays. 15:1993;815-824.
6. Peles E, Bacus S S, Koski R A. Isolation of the neu/ HER2 stimulatory ligand: a 44KD glycoprotein that induces differentiation of mammary tumour cells. Cell. 69:1992;205-216.
7. Tzahar E, Levkowitz G, Karunagarau D. ErbB3 and ErbB4 function as the respective low and high affinity receptors of all neu differentiation factor heregulin isoforms. J Biol Chem. 259:1994;25226-25233.
8. Muller W J, Sinn E, Pattengale P K, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54:1988;105.
9. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
10. Varley J M, Swallow J E, Brammar W J, Whittaker J L, Walker R A. Alterations to either c- erb B-2 (neu) or c- myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1:1987;423-430.
11. Zhou D, Battifora H, Yokata J, Yamamoto T, Cline M J. Association of multiple copies of the c-erbB-2 oncogene with the spread of breast cancer. Cancer Res. 47:1987;6123-6125.
12. Borresen A-L, Ottestad L, Gaustad A. Amplification and protein over-expression of the neu/ HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer. 62:1990;585-590.
13. Zhou D, Ahuja H, Cline M J. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene. 4:1989;105-108.
14. Clark G M, McGuire W L. Follow-up study of HER-2 amplification in primary breast cancer. Cancer Res. 51:1991;944-948.
15. van de Vijver M, van de Bersselaar R, Devilee P, Corneliesse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 7:1987;2019-2023.
16. Walker R A, Senior P V, Jones J L, Critchley D R, Varley J M. An immunohistochemical and in-situ hybridisation study of c-myc and c-erbB-2 expression in primary breast tumours. J Pathol. 158:1989;97-105.
17. Venter D J, Tuzi N L, Kumar S, Gullick W J. Over-expression of the c- erb B-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet. 2:1987;69-72.
18. Barnes D M, Lammie G A, Millis R R, Gullick W L, Allen B S, Altman D G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinomas. Br J Cancer. 58:1988;448-452.
19. O'Reilly S M, Barnes D M, Camplejohn R S, Bartkova J, Gregory W M, Richards M A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 63:1991;444-446.
20. Walker R A, Gullick W J, Varley J M. An evaluation of immunoreactivity for c-erb-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer. 60:1989;426-429.
21. Lovekin C, Ellis I O, Locker A. C-erbB-2 oncogene expression and prognosis in operable breast cancer. Br J Cancer. 63:1991;439-443.
22. Gullick W J, Love S B, Wright C. C-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 63:1991;434-438.
23. van de Vijver M J, Peterse J L, Mooi W J. Neu-protein overexpression in breast cancer. New Eng J Med. 319:1988;1239-1245.
24. Bartkova J, Barnes D M, Millis R R, Gullick W J. Immunohistochemical detection of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol. 21:1990;1164-1167.
25. Allred D C, Clark G M, Molina R. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 23:1992;974-979.
26. Nicholson R I, McClelland R A, Finlay P. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 29A:1993;1018-1023.
27. Newby J C, Johnston S R D, Smith I E, Dowsett M. Expression of epidermal growth factor receptor and c-erbB-2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 3:1997;1643-1651.
28. Elledge R A, Green S, Ciocca D. HER-2 expression and response to tamoxifen in oestrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 4:1998;7-12.
29. Stal O, Sullivan S, Wingren S. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 31A:1995;2185-2190.
30. Miles D W, Harris W H, Gillett C E, Smith P, Barnes D M. Effect of c-erbB-2 and oestrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer. 84:1999;354-359.
31. Paik S, Byrant J, Park C. erbB-2 and response to doxorubucin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 90:1998;1361-1370.
32. HER2antibody for human cancer treatment. Proc Natl Acad Sci USA. 89:1992;4285-4289.
33. Press M F, Hung G, Godolphin W, Slamon D J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 54:1994;2771-2777.
34. Press M F, Pike M C, Chasin V R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerised image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:1993;4960-4970.
35. Penault-Llorca F, Adelaide J, Houvenaeghee G, Hassoun J, Birnbaum D, Jacquemier J. Optimisation of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 173:1994;63-75.
36. Farabegoli F, Ceccarelli C, Santini D. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer (Pred Oncol). 84:1999;273-277.
37. Jacobs T W, Gown A M, Yaziji H, Barnes M J, Schnitt S J. Specificity of Hercep Test in determining HER-2/neu status of breast cancers using the United States food and drug administration-approved scoring system. J Clin Oncol. 17:1999;1983-1987.
38. Pauletti G, Godolphin W, Press M F, Slamon D J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridisation. Oncogene. 13:1996;63-72.
39. Jacobs T W, Gown A M, Yaziji H, Barnes M J, Schnitt S J. Comparison of fluorescence in situ hybridisation and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 17:1999;1974-1982.